Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTHGet Rating) in a note issued to investors on Monday. The brokerage set a “sell” rating on the stock.

Bio-Path Price Performance

Shares of BPTH opened at $1.48 on Monday. Bio-Path has a 1 year low of $1.29 and a 1 year high of $5.28. The company has a market capitalization of $10.60 million, a price-to-earnings ratio of -0.75 and a beta of 1.39. The business has a 50-day moving average of $2.97 and a 200-day moving average of $3.44.

Institutional Investors Weigh In On Bio-Path

Several large investors have recently added to or reduced their stakes in BPTH. Virtu Financial LLC acquired a new stake in Bio-Path during the first quarter worth approximately $38,000. Renaissance Technologies LLC acquired a new stake in Bio-Path during the second quarter worth approximately $70,000. Mount Yale Investment Advisors LLC acquired a new stake in Bio-Path during the third quarter worth approximately $81,000. Finally, Citadel Advisors LLC acquired a new stake in Bio-Path during the third quarter worth approximately $35,000. Institutional investors and hedge funds own 5.76% of the company’s stock.

About Bio-Path

(Get Rating)

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Featured Stories

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.